NanoBio is a private biotech company developing intranasal vaccines based on a proprietary nanotechnology platform discovered at the University of Michigan. The company's vaccines uniquely elicit both systemic and mucosal immunity. NanoBio has an ongoing collaboration with Sanofi Pasteur for an intranasal pertussis vaccine, and has contracts from the U.S. National Institutes of Health funding four additional intranasal vaccine programs.